Vaginal melanoma and the role of regional chemotherapy

Mh, Beg; Jh, Muchmore; Rd, Carter; Et, Krementz

doi:10.1002/jso.2930530217

Cited by 7 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Local chemotherapy has been previously trialed to downsize tumors and ensure local control (28). In a study from Harting et al (29), a partial response was observed in 36% of the 11 patients treated with systemic chemotherapy, and the median survival time was 10 months.…”

Section: Discussionmentioning

confidence: 99%

Malignant melanoma of the vagina: A case report and review of the literature

et al. 2014

View full text Add to dashboard Cite

Primary malignant melanoma of the vagina is an extremely rare variant of melanoma that accounts for <3% of all vaginal malignancies. Primary malignant melanoma of the vagina has a worse prognosis as compared with non-genital melanomas or other vaginal malignant neoplasms. A-35-year-old female had a diagnosis of primary malignant melanoma of the vagina. A local excision of the tumor was first performed, followed by a radical excision as a further therapeutic measure. The patient returned after three weeks, presenting with a vesico-vaginal fistula. A conservative operation was subsequently performed in order to improve the quality of life of the patient. Pelvic metastases were identified 6 months after the completion of the last surgical therapy and subsequent follow-up examinations were performed in another hospital. The present case study describes the clinical features and surgical procedures of this patient with primary malignant melanoma of the vagina. In conclusion, melanoma of the vagina is an extremely aggressive cancer and the overall prognosis is poor despite the various treatment options.

show abstract

Section: Discussionmentioning

confidence: 99%

Malignant melanoma of the vagina: A case report and review of the literature

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Adjuvant therapy such as interferon‐α, interferon‐α2b, interleukin‐2, vaccine therapy, and cytotoxic chemotherapy, eg, DTIC have been described for the treatment of melanomas ( 6,7, 13,19 ) . Interferon‐α has also been shown to confer survival benefits in patients with nodal disease ( 13 ) .…”

Section: Discussionmentioning

confidence: 99%

Vaginal malignant melanoma: a case report and literature review

Moodley¹,

Daya²,

Moodley³

2004

Int J Gynecol Cancer

View full text Add to dashboard Cite

Vaginal melanomas are rare genital malignancies occurring mainly in the 6th and 7th decades of life. In general, they have a worse prognosis than cutaneous melanomas. In the past, various treatment modalities have been recommended including radical pelvic surgery. However, the prognosis is poor in spite of such radical approaches. More recently, more conservative treatment in the form of wide local excision combined with adjuvant chemotherapy, high-dose radiotherapy, and immunotherapy seem to have promising results. We describe a patient with vaginal malignant melanoma treated with conservative local excision as well as adjuvant radiotherapy, chemotherapy, and interferon.

show abstract

“…Adjuvant therapy such as interferon-a, interferon-a2b, interleukin-2, vaccine therapy, and cytotoxic chemotherapy, eg, DTIC have been described for the treatment of melanomas (6,7,13,19) . Interferon-a has also been shown to confer survival benefits in patients with nodal disease (13) .…”

Section: Discussionmentioning

confidence: 99%